Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Launches Fast-Track Monitoring Of Crucial COVID-19 Drug Shortages

Executive Summary

A new system for monitoring the availability of medicines for treating COVID-19 patients will allow EU-level coordinated actions to address supply shortages in the best way. 

You may also be interested in...

COVID-19 Drug Shortages: EU Explores Tweaking National Forecasting Models

As COVID-19-related drug shortages continue to persist in the EU, regulators explore the possibility of drawing lessons from existing models that member states use to estimate national demand for medicines. 

Decisive Action Called For On EU Drug Shortages

A public health advocacy group in the EU has issued tangible recommendations to address the perennial problem of drug shortages in the region.

Global Regulators Explore Alignment Options During COVID-19

Supporting convergence, allowing greater regulatory flexibility and avoiding drug shortages were among key topics discussed by global regulators at the first of a series of bi-weekly exchanges organized by the International Coalition of Medicines Regulatory Authorities.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts